Alight Launches GLP-1 HRA Solution to Tackle Rising Drug Costs
Event summary
- Alight introduced a GLP-1 Health Reimbursement Account (HRA) solution to help employers manage access and costs of GLP-1 medications.
- GLP-1 drugs accounted for 42% of prescriptions reviewed in Alight’s Navigation book of business, up from 32% in 2024.
- 16% of GLP-1 drug reviews identified lower-cost alternatives, saving an average of $2,790 annually per prescription.
- The solution allows employers to set reimbursement limits, funding models, and monitor claims in real-time.
The big picture
Alight’s GLP-1 HRA solution addresses a growing challenge for employers: managing the rising cost and utilization of GLP-1 medications. As these drugs become more prevalent in employee benefits strategies, Alight aims to provide a structured way to offer financial support while maintaining cost control. The solution reflects broader industry trends toward personalized benefits management and data-driven cost optimization in healthcare.
What we're watching
- Cost Management
- How employers will balance GLP-1 medication access with cost control using Alight’s flexible HRA solution.
- Market Adoption
- The pace at which employers adopt this solution as GLP-1 drug utilization continues to rise.
- Regulatory Compliance
- Whether Alight’s solution will maintain compliance with IRS rules as employers integrate it with HSAs/HDHPs.
Related topics
